Opinion|Videos|January 27, 2025
Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC
Panelists discuss how, PDS0101 uses Versamune® lipid nanoparticles to deliver HPV16 antigens, activating T-cells. Early Phase 2 data with pembrolizumab showed promise in HPV16+ head & neck cancer patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe the mechanism of action of the novel Versamune (PDS0101) HPV-16 targeted cancer vaccine.
- Please discuss the recent data presented for the Phase 2 VERSATILE-002 study of PDS0101 + pembrolizumab in adults with HPV16 and PD-L1 positive recurrent/metastatic HNSCC.
- Weiss et al. ESMO 2024
- Versatile-002 - 879P - ESMO 2024
Advertisement
Related to this article
Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5